How big is TriSalus Life Sciences, Inc.?

As of Jun 18, TriSalus Life Sciences, Inc. has a market capitalization of 196.38 million, with net sales of 32.14 million and a net profit of -27.22 million over the last four quarters. The company's shareholder's funds are -25.89 million, and total assets are 23.97 million.

Market Cap: As of Jun 18, TriSalus Life Sciences, Inc. has a market capitalization of 196.38 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, TriSalus reported net sales of 32.14 million and a net profit of -27.22 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds stood at -25.89 million, while total assets were reported at 23.97 million.

What does TriSalus Life Sciences, Inc. do?

TriSalus Life Sciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $9 million and a net loss of $10 million as of March 2025, with a market cap of $196.38 million. Key metrics include a negative P/E ratio and a return on equity of 105.18%.

Overview: <BR>TriSalus Life Sciences, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 9 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -10 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 196.38 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.55 <BR>Return on Equity: 105.18% <BR>Price to Book: -5.71<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Should I buy, sell or hold TriSalus Life Sciences, Inc.?

Is TriSalus Life Sciences, Inc. overvalued or undervalued?

As of February 9, 2023, TriSalus Life Sciences, Inc. is considered a risky investment due to its negative financial ratios and underperformance compared to peers and the S&P 500.

As of 9 February 2023, the valuation grade for TriSalus Life Sciences, Inc. moved from does not qualify to risky. The company appears to be overvalued given its negative financial ratios, including a price to book value of -5.93 and an EV to EBITDA of -7.25. The negative return on capital employed and return on equity further underscore the financial challenges facing the company.<BR><BR>In comparison to its peers, TriSalus's P/E ratio is -5.43, while Altimmune, Inc. has a P/E of -6.19 and Harpoon Therapeutics, Inc. shows a much larger negative P/E of -28.51. The overall market sentiment reflects poorly on TriSalus, as evidenced by its recent stock performance, which has underperformed the S&P 500 across various time frames, including a 1-year return of -7.03% compared to the S&P 500's 10.26%.

Is TriSalus Life Sciences, Inc. technically bullish or bearish?

As of August 18, 2025, TriSalus Life Sciences, Inc. shows a mildly bearish trend overall, with mixed technical indicators and underperformance compared to the S&P 500, reflecting a year-to-date return of -1.8% versus 12.22%.

As of 18 August 2025, the technical trend for TriSalus Life Sciences, Inc. has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD also shows mildly bullish. However, the daily moving averages are mildly bearish, and the Bollinger Bands on a monthly basis are bearish. The KST presents a mixed view with a weekly bearish signal and a mildly bullish monthly signal. Overall, there is no clear trend indicated by Dow Theory or OBV.<BR><BR>In terms of performance, TriSalus has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -1.8% versus the S&P 500's 12.22%, and a one-year return of 6.49% compared to 17.14%. This suggests a weaker technical stance despite some mildly bullish indicators.